Literature DB >> 26928314

Potential Therapy for Refractory Colon Cancer.

Mitch Leslie.   

Abstract

The drug MM-1151 may overcome resistance to cetuximab and panitumumab caused by some mutations in the extracellular domain of EGFR. The drug slowed disease progression in a colorectal cancer cell line that carried some of the mutations and curbed growth of cells derived from a cetuximab-resistant patient tumor. In a phase I trial, tumors shrank or stabilized in patients who carried the mutations and received the drug. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26928314     DOI： 10.1158/2159-8290.CD-NB2016-021

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  3 in total

Review 1.  Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.

Authors:  Alessia Bignucolo; Elena De Mattia; Erika Cecchin; Rossana Roncato; Giuseppe Toffoli
Journal:  Int J Mol Sci       Date:  2017-07-14       Impact factor: 5.923

2.  Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance.

Authors:  Moiez Ali; Erin Kaltenbrun; Gray R Anderson; Sarah Jo Stephens; Sabrina Arena; Alberto Bardelli; Christopher M Counter; Kris C Wood
Journal:  Nat Commun       Date:  2017-06-08       Impact factor: 14.919

3.  S645C Point Mutation Suppresses Degradation of EGFR to Promote Progression of Glioblastoma.

Authors:  Wenda Huang; Ling Zou; Zhaonian Hao; Baofeng Wang; Feng Mao; Qiuhong Duan; Dongsheng Guo
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.